Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 49Brain Neoplasms 26Central Nervous System Neoplasms 22Astrocytoma 17Glioma 16Medulloblastoma 11Neoplasms 8Oligodendroglioma 7Recurrence 6Gliosarcoma 6Spinal Cord Neoplasms 2Ependymoma 2Sarcoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Familial ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Spermine Synthase 1Radiosurgery 1Modafinil 1Mental Status and Dementia Tests 1Lovastatin 1Lomustine 1Lamotrigine 1DNA Methylation 1Cognitive Training 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cognition Disorders × Lomustine × CNS × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡